ClinicalTrials.gg
RecruitingNCT05858983Updated May 15, 2023

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

A Phase 1/2 interventional study of FT-001 Low Dose and FT-001 Mid Dose in Biallelic RPE65 Mutation-associated Retinal Dystrophy, sponsored by Frontera Therapeutics. Recruiting at 1 site in China. Open to participants aged 8 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Frontera Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Nov 2022, registered Apr 2023).
  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
8 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Retinal Dystrophies with a site in China — 6 open to participants now, 9 under way, 1 of them phase 3. Retinal Dystrophies · China.

Started
2022
with 1 other
Phase 1/2
2 of 10
1 open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Frontera Therapeutics

Among the 10 studies in Retinal Dystrophies with a site in China, this one is one of 2 that started in 2022, is one of 2 in phase 1/2, and was the 3rd registered.

Retinal Dystrophies

60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.

Browse Retinal Dystrophies studies →

Open to participants now

6 of the 10 studies in Retinal Dystrophies with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 8 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Retinal Dystrophies with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of subretinal administration of FT-001 in subjects with biallelic RPE65 mutation-associated retinal dystrophy.

Read the detailed description

This study is a multi-center, open-label, phase I/II clinical study to evaluate the safety, tolerability, efficacy, immunogenicity, and in vivo biodistribution characteristics of FT-001 in subjects with biallelic RPE65 mutation-associated retinal dystrophy. Assessments will include visual acuity, vector shedding, immunogenicity and adverse events. Participants will be monitored for 5 years after treatment.

03

Conditions studied

  • Biallelic RPE65 Mutation-associated Retinal Dystrophy

Browse trials for

Keywords

  • FT-001
  • Biallelic RPE65 Mutation-associated Retinal Dystrophy
04

Who can participate

Ages eligible
8 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are able to understand and sign the ICF
  2. Female or male aged 8-45 years old when signing the ICF
  3. Clinically diagnosed with biallelic RPE65 mutation-associated retinal dystrophy

Exclusion criteria

Exclusion Criteria:

  1. Other interfering eye diseases
  2. Presence of any systemic or ocular disease that can cause or likely to cause vision loss
  3. There is evidence of obviously uncontrolled concomitant diseases
  4. Known to have active or suspected diseases
  5. With active systemic infection under treatment
  6. Pregnant or lactating women
  7. Other conditions unsuitable for the study as determined by the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    FT-001 Dose 1

    Intraocular administration of a single low dose of range FT-001

    Genetic: FT-001 Low Dose

  • Experimental
    FT-001 Dose 2

    Intraocular administration of a single Mid dose of range FT-001

    Genetic: FT-001 Mid Dose

  • Experimental
    FT-001 Dose 3

    Intraocular administration of a single High dose of range FT-001

    Genetic: FT-001 High Dose

Interventions

  • GeneticFT-001 Low Dose

    Comparison of different dosages of FT-001

  • GeneticFT-001 Mid Dose

    Comparison of different dosages of FT-001

  • GeneticFT-001 High Dose

    Comparison of different dosages of FT-001

06

What researchers measure

Primary outcomes

  1. Safety of FT-001(incidence of ocular and non-ocular AEs and SAEs)

    Incidence of ocular and non-ocular AEs and SAEs

    Time frame: 52 weeks

Secondary outcomes

  1. Changes in visual function from baseline

    Changes in visual function from baseline as assessed by FST

    Time frame: 52 weeks

  2. Changes in visual function from baseline

    Changes in visual function from baseline as assessed by Mobility courses

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Nov 2025, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2023
First posted
May 15, 2023
StartActual
Nov 30, 2022
Primary completionEst.
Nov 30, 2025
CompletionEst.
Nov 30, 2029
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05858983
Lead sponsor
Frontera Therapeutics
Responsible party
Sponsor
First posted
May 15, 2023
Start date
Nov 30, 2022
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
May 15, 2023

Study contacts

Xinyan Li
Contact
Xinyan.li@fronteratherapeutics.com
+86-021-58206061
Minghui Xue
Contact
minghui.xue@fronteratherapeutics.com
+86-021-58206061
Ruifang Sui
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion